Patents Assigned to New England Medical Center Hospitals
  • Patent number: 5750353
    Abstract: The invention features a method for determining whether a candidate compound is a non-peptide agonist of a peptide hormone receptor. In this method, a candidate compound is exposed to a form of the peptide hormone receptor which has an enhanced ability to amplify the intrinsic activity of a non-peptide agonist. The second messenger signaling activity of the enhanced receptor is measured in the presence of the candidate compound, and compared to the second messenger signaling activity of the enhanced receptor measured in the absence of the candidate compound. A change in second messenger signaling activity indicates that the candidate compound is an agonist. An increase in second messenger signaling activity indicates that the compound is either a full or partial positive agonist; a decrease in second messenger signaling activity indicates that the compound is an inverse (also termed a `negative`) agonist.
    Type: Grant
    Filed: December 11, 1995
    Date of Patent: May 12, 1998
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: Alan S. Kopin, Martin Beinborn
  • Patent number: 5744348
    Abstract: A protein having the biological activity of a mammalian TSH receptor, and purified nucleic acid encoding such a protein.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: April 28, 1998
    Assignee: New England Medical Center Hospitals, Inc.
    Inventor: Roger D. Cone
  • Patent number: 5736377
    Abstract: The expression and purification of normal epithelial specific polypeptide (NES1) which is expressed in normal cells, but not in radiation transformed cells, are described. Both the DNA sequence encoding the NES1 and the corresponding amino acid sequence are disclosed. Also, disclosed are methods for carcinoma detection and treatment using the NES1 as well as methods of identifying compounds modulating the expression and activity of NES1.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 7, 1998
    Assignee: New England Medical Center Hospitals, Inc.
    Inventor: Vimla Band
  • Patent number: 5728534
    Abstract: The invention features screening methods which can be used to identify agents, known as vasoprotective agents, which inhibit vascular smooth muscle cell activation and/or proliferation or enhance vascular endothelial cell activation and/or proliferation or activate estrogen responsive genes in vascular cells. Preferred vasoprotective agents are relatively vasospecific, i.e., their effect on one or more types of vascular cells is more pronounced than their effect on other cell types. Treatment with such vasospecific agents will generally be associated with fewer undesirable side-effects than treatment with estrogen.The methods of the invention are screening assays in which candidate agents are examined to identify vasoprotective agents. One type of screening assay involves examining the effect of a candidate agent on cell proliferation and/or cell activation. Another type of screening assay involves examining the effect of a candidate agent on the expression of a gene which is responsive to estrogen.
    Type: Grant
    Filed: July 19, 1996
    Date of Patent: March 17, 1998
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: Michael E. Mendelsohn, Richard H. Karas
  • Patent number: 5718233
    Abstract: An instrument for continuously monitoring the condition of a patient who has a cardiovascular disease, the instrument including an electrocardiograph; a waveform analyzer which analyzes a current segment of an ECG waveform; a computer receiving output from the waveform analyzer; and a control module. The computer is programmed to complete a monitoring cycle in which the computer uses the output from the waveform analyzer to compute a probability of a life threatening cardiac condition based upon the current segment of the patient's ECG waveform. The control module causes the computer to periodically repeat the monitoring cycle and for each repetition of said monitoring cycle to compute a change-of-condition measure, wherein the change-of-condition measure is calculated by subtracting a computed probability for a previous monitoring cycle from the computed probability for the current monitoring cycle.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: February 17, 1998
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: Harry P. Selker, John L. Griffith
  • Patent number: 5714325
    Abstract: A method for detecting presence or absence of a nucleic acid of interest in fetal nucleic acid derived from a sample of peripheral blood obtained from a pregnant woman is described. The method involves obtaining a sample of peripheral blood from a pregnant woman, treating the sample of peripheral blood such that fetal nucleic acid present in fetal granulocytes is made available for detection and detecting presence or absence of a nucleic acid of interest in the available fetal nucleic acid. The proportion of fetal granulocytes present in the sample of peripheral blood can be increased relative to the sample of peripheral blood forming a sample enriched in fetal granulocytes prior to the detection step.
    Type: Grant
    Filed: September 24, 1993
    Date of Patent: February 3, 1998
    Assignee: New England Medical Center Hospitals
    Inventor: Diana W. Bianchi
  • Patent number: 5674722
    Abstract: Endothelial cells transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced endothelial cells are disclosed. Such endothelial cells are useful in improving the performance of vascular grafts and in delivering the encoded polypeptide or protein, such as an enzyme, a hormone, a receptor or a drug, to an individual.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: October 7, 1997
    Assignees: Somatix Therapy Corporation, Whitehead Institute For Biomedical Research, Brigham & Womens Hospital, Howard Hughes Medical Institute, New England Medical Center Hospitals
    Inventors: Richard C. Mulligan, Lawrence K. Cohen, Lori F. Rafield, Louis K. Birinyi, Allan D. Callow, James M. Wilson
  • Patent number: 5674835
    Abstract: A method of inhibiting the growth of a virus, the DNA of the virus including the nucleic acid sequence 5' ACCXNNNPyCGGTXY3', wherein each N, X, and Y is, independently, any nucleotide, and Py is C or T, the nucleic acid sequence being capable of binding to a protein encoded by the DNA of the virus, the protein, upon binding to the nucleic acid sequence, being capable of causing the enhancement of the transcription of DNA of the virus, the method including inhibiting the protein from binding to the nucleic acid sequence to repress the transcription of DNA of said virus to inhibit the growth of the virus.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 7, 1997
    Assignees: New England Medical Center Hospitals, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Elliot J. Androphy, Douglas R. Lowy, John T. Schiller
  • Patent number: 5669380
    Abstract: A laryngeal bypass device for transcutaneous insertion into a human sublaryngeal trachea has an outer tubular member coupled to an aspiration device and an inner tubular member disposed within the outer tubular member and coupled to a ventilation device. The inner tubular member delivers oxygenated air from the ventilation device to the lungs, and the outer tubular member aspirates carbon dioxide from the lungs. By utilizing the two tubular members in a single bypass device, adequate ventilation of the lungs occurs without the need for air evacuation through the mouth, as the larynx is completely bypassed. In one embodiment, the laryngeal bypass device further includes a barrier member coupled to the inner tubular member for maintaining the outer and inner tubular members free of surrounding tissue during respiration.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: September 23, 1997
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: Brendan P. Garry, Peak Woo
  • Patent number: 5667965
    Abstract: This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. Native full-length E2 trans-activation protein activates transcription of papillomavirus only through binding to DNA, and it binds to DNA only in the form of a pre-formed homodimer--a pair of identical polypeptide subunits held together by non-covalent interactions. The E2 trans-activation repressors of this invention are proteins, polypeptides or other molecules that dimerize with full-length native E2 polypeptides to form inactive heterodimers, thus interfering with the formation of active homodimers comprising full-length native E2 polypeptides, thereby repressing papillomavirus transcription and replication. The E2 trans-activation repressors of this invention are advantageously used in the treatment of papillomavirus infections and their associated diseases.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: September 16, 1997
    Assignees: Biogen, Inc., New England Medical Center Hospitals, Inc.
    Inventors: Elliot J. Androphy, James G. Barsoum
  • Patent number: 5656599
    Abstract: This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. Native full-length E2 trans-activation protein activates transcription of papillomavirus only through binding to DNA, and it binds to DNA only in the form of a pre-formed homodimer--a pair of identical polypeptide subunits held together by non-covalent interactions. The E2 trans-activation repressors of this invention are proteins, polypeptides or other molecules that dimerize with full-length native E2 polypeptides to form inactive heterodimers, thus interfering with the formation of active homodimers comprising full-length native E2 polypeptides, thereby repressing papillomavirus transcription and replication. The E2 trans-activation repressors of this invention are advantageously used in the treatment of papillomavirus infections and their associated diseases.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: August 12, 1997
    Assignees: Biogen, Inc., New England Medical Center Hospitals, Inc.
    Inventors: Elliot J. Androphy, James G. Barsoum
  • Patent number: 5648220
    Abstract: The invention features a method of labeling a cell containing an intracytoplasmic target molecule involving (1) permeabilizing the plasma membrane of the cell so that (a) a reagent capable of detectably labeling the intracytoplasmic target molecule can traverse the plasma membrane into the cytoplasm of the cell; and (b) substantially all of the intracytoplasmic target molecule and the DNA of the cell remain in the cell; and (2) contacting the cell with the reagent to label the intracytoplasmic target molecule. The method may further involve detecting the label in the cell, and isolating the cell on the basis of detecting the label in the cell. The invention also includes cells permeabilized using the method of the invention.
    Type: Grant
    Filed: February 14, 1995
    Date of Patent: July 15, 1997
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: Diana W. Bianchi, Mary Ann DeMaria
  • Patent number: 5616559
    Abstract: This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. Native full-length E2 trans-activation protein activates transcription of papillomavirus only through binding to DNA, and it binds to DNA only in the form of a pre-formed homodimer--a pair of identical polypeptide subunits held together by non-covalent interactions. The E2 trans-activation repressors of this invention are proteins, polypeptides or other molecules that dimerize with full-length native E2 polypeptides to form inactive heterodimers, thus interfering with the formation of active homodimers comprising full-length native E2 polypeptides, thereby repressing papillomavirus transcription and replication. The E2 trans-activation repressors of this invention are advantageously used in the treatment of papillomavirus infections and their associated diseases.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: April 1, 1997
    Assignees: Biogen, Inc., New England Medical Center Hospitals, Inc.
    Inventors: Elliot J. Androphy, James G. Barsoum
  • Patent number: 5614363
    Abstract: A protein having the biological activity of a mammalian TSH receptor, and purified nucleic acid encoding such a protein.
    Type: Grant
    Filed: October 29, 1993
    Date of Patent: March 25, 1997
    Assignee: New England Medical Center Hospitals, Inc.
    Inventor: Roger Cone
  • Patent number: 5595884
    Abstract: This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. This invention also relates to DNA sequences and recombinant DNA molecules encoding such repressors, unicellular hosts transformed with such DNA molecules, and processes for producing and using such repressors. Native full-length E2 trans-activation protein activates transcription of papillomavirus only through binding to DNA, and it binds to DNA only in the form of a pre-formed homodimer--a pair of identical polypeptide subunits held together by non-covalent interactions. The E2 trans-activation repressors of this invention are proteins, polypeptides or other molecules that dimerize with full-length native E2 polypeptides to form inactive heterodimers, thus interfering with the formation of active homodimers comprising full-length native E2 polypeptides, thereby repressing papillomavirus transcription and replication.
    Type: Grant
    Filed: September 24, 1993
    Date of Patent: January 21, 1997
    Assignees: Biogen Inc., New England Medical Center Hospitals, Inc.
    Inventors: Elliot J. Androphy, James G. Barsoum
  • Patent number: 5585465
    Abstract: The invention relates to the isolated toxin associated with Kawasaki syndrome and the bacteria from which these are isolated.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: December 17, 1996
    Assignees: National Jewish Center for Immunology and Respiratory Medicine, New England Medical Center Hospital, Inc., Regents of the University of Minnesota
    Inventors: Donald Leung, Patrick Schlievert, Cody Meissner
  • Patent number: 5541071
    Abstract: The invention features purified nucleic acids encoding the mammalian gastrin/CCK-B receptor family. The invention also features a) the gastrin and CCK-B receptor polypeptides, b) a method of identifying antagonists to the gastrin or CCK-B receptors, and c) a parietal cell cDNA expression library.
    Type: Grant
    Filed: November 12, 1992
    Date of Patent: July 30, 1996
    Assignee: New England Medical Center Hospitals, Inc.
    Inventor: Alan S. Kopin
  • Patent number: 5534544
    Abstract: A method of inhibiting the growth of Helicobacter pylori is described. The method involves administering to a mammal a composition containing a surfactant/emulsifying agent and which is substantially free of calcium, magnesium, aluminum and silicon ions.
    Type: Grant
    Filed: August 19, 1994
    Date of Patent: July 9, 1996
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: Andrew G. Plaut, Anne V. Kane
  • Patent number: 5520680
    Abstract: A method is provided for facilitating the atrophying of a tonsil or adenoid ("organ") to cause the gradual removal thereof from the patient. A laser is positioned adjacent the organ, the wavelength for the laser being in the 700 nm to 1100 nm range and having energy sufficient to cause coagulation of blood in at least a significant number of the organ vessels over a period of several minutes, but not so much energy as to kill significant tissue of the organ or to cause significant damage to tissue adjacent to the organ. The laser is then turned on to irradiate the organ with laser energy and the entire exposed area of the organ is painted or otherwise irradiated. Irradiation continues until a selected condition of the organ, tissue adjacent the organ and/or laser source occurs.
    Type: Grant
    Filed: June 22, 1995
    Date of Patent: May 28, 1996
    Assignee: New England Medical Center Hospital, Inc.
    Inventors: Stanley M. Shapshay, Michail M. Pankratov
  • Patent number: 5510462
    Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes-stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.
    Type: Grant
    Filed: April 25, 1988
    Date of Patent: April 23, 1996
    Assignees: New England Medical Centers Hospitals, Inc., Trustees of Tufts College, Wellesley College, Massachusetts Institute of Technology
    Inventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff